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Summary
Background Lymphatic ﬁ lariasis is targeted for elimination as a public health problem by 2020. The principal approach 
used by current programmes is annual mass drug administration with two pairs of drugs with a good safety proﬁ le. 
However, one dose of a triple-drug regimen (ivermectin, diethylcarbamazine, and albendazole) has been shown to 
clear the transmissible stage of the helminth completely in treated individuals. The aim of this study was to use 
modelling to assess the potential value of mass drug administration with the triple-drug regimen for accelerating 
elimination of lymphatic ﬁ lariasis in diﬀ erent epidemiological settings.
Methods We used three diﬀ erent transmission models to compare the number of rounds of mass drug administration 
needed to achieve a prevalence of microﬁ laraemia less than 1% with the triple-drug regimen and with current 
two-drug regimens.
Findings In settings with a low baseline prevalence of lymphatic ﬁ lariasis (5%), the triple-drug regimen reduced the 
number of rounds of mass drug administration needed to reach the target prevalence by one or two rounds, compared 
with the two-drug regimen. For areas with higher baseline prevalence (10–40%), the triple-drug regimen strikingly 
reduced the number of rounds of mass drug administration needed, by about four or ﬁ ve, but only at moderate-to-high 
levels of population coverage (>65%) and if systematic non-adherence to mass drug administration was low.
Interpretation Simulation modelling suggests that the triple-drug regimen has potential to accelerate the elimination 
of lymphatic ﬁ lariasis if high population coverage of mass drug administration can be achieved and if systematic 
non-adherence with mass drug administration is low. Future work will reassess these estimates in light of more 
clinical trial data and to understand the eﬀ ect on an individual country’s programme.
Funding Bill & Melinda Gates Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
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Introduction
Lymphatic ﬁ lariasis is a neglected tropical disease caused 
by ﬁ larial nematodes that is prevalent in large parts of the 
tropics and subtropics.1 Currently, 790 million people are at 
risk of the disease and 68 million are infected, with a 
further 20 million suﬀ ering from chronic morbidity.2–4 
In 2000, the Global Programme to Eliminate Lymphatic 
Filariasis (GPELF) was launched by WHO with the primary 
goal of global elimination of ﬁ lariasis through mass drug 
administration of pairs of anthelmintic drugs (albendazole 
in combination with either ivermectin or diethyl-
carbamazine).5 The campaign has seen unprece dented 
scale-up, with 22 countries currently undergoing mass 
drug administration at full geographic coverage and a 
further 18 countries in surveillance after mass drug 
administration. This programme was made possible by 
donation of diethylcarbamazine citrate by Eisai, albendazole 
by GlaxoSmithKline, and ivermectin by Merck.
Current guidelines require at least ﬁ ve rounds of 
mass drug administration, resulting in a microﬁ laraemia 
prevalence of less than 1%, as measured using a trans-
mission assessment survey across an implementation 
unit, preceded by an initial pre-transmission assessment 
survey at particular sites.6,7 These programmes have 
resulted in huge health gains internationally among low-
income populations.6 However, in 2014, 11 countries had 
yet to begin their mass drug administration programmes; 
moreover, some districts or other focused areas in several 
countries have not yet reached elimination targets despite 
10 years or more of mass drug administration.8 Several 
factors can lead to a programme failing to reach its 
targets—eg, high prevalence of ﬁ lariasis, poor population 
coverage, partial eﬀ ectiveness of drug regimens, 
inadequate dose received, non-adherence because of fear 
of side-eﬀ ects, and failure for medicine to be delivered.9–12 
For these scenarios, new strategies are needed to achieve 
the elimination goals by 2020.
Findings of a clinical trial suggested that, by 
combining the three drugs used to treat lymphatic 
ﬁ lariasis (ivermectin, diethylcarbamazine, and 
albendazole), improved eﬃ  cacy for clearing the 
transmissible stage of the ﬁ larial parasite Wuchereria 
bancrofti (microﬁ lariae) and sterilising adult ﬁ larial 
worms could be achieved.13  The safety and eﬃ  cacy of 
this promising regimen for widespread use is the 
subject of ongoing study. However, the triple-drug 
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regimen would not be suitable for all areas where 
lymphatic ﬁ lariasis is endemic because of contra-
indications for diethylcarbamazine in regions where 
onchocerciasis is endemic and for ivermectin in areas 
where loiasis is endemic. Nevertheless, a triple-drug 
regimen of ivermectin, diethylcarbamazine, and 
albendazole holds great promise.
The additional value of the triple-drug regimen at the 
population level—for reaching elimination targets more 
quickly and with fewer rounds of mass treatment 
compared with standard two-drug regimens—is a crucial 
factor in the consideration of any change in use and must 
be investigated for expected-use cases and scenarios. 
Mathematical modelling can play a part by simulating 
diﬀ erent scenarios and assessing the likely eﬀ ect of a 
triple-drug regimen under diﬀ erent assumptions.
We used three state-of-the-art lymphatic ﬁ lariasis trans-
mission models to assess the likely eﬀ ect of the triple-
drug regimen of ivermectin, diethylcarbamazine, and 
albendazole in several scenarios, to understand the 
extent of any potential beneﬁ t of the triple-drug regimen 
over the standard two-drug strategy, and to investigate 
the conditions under which this beneﬁ t is most 
pronounced. Three models provide far greater robustness 
and quantiﬁ cation of uncertainty in prediction versus 
use of one model. Five broad scenarios are considered 
from various plausible settings in which both the 
dominant vector species and the baseline prevalence of 
microﬁ lariae are varied to reﬂ ect the current global 
situation of lymphatic ﬁ lariasis endemicity. These 
scenarios include areas where no previous mass drug 
administration campaign has been undertaken and those 
where ﬁ ve rounds of mass drug administration were 
insuﬃ  cient to reduce the prevalence of infection to the 
target of less than 1% needed for stopping mass drug 
administration.
Methods
Study design
Clinical trial ﬁ ndings suggest that microﬁ lariae clearance 
by ivermectin, diethylcarbamazine, and albendazole is 
likely to be 100%.13 Ongoing studies will reﬁ ne this 
estimate; therefore, our analysis is for the most optimistic 
eﬀ ect. In view of the evidence from the clinical trial, 
we made two plausible eﬃ  cacy assumptions for the new 
triple-drug regimen on adult worms (appendix p 2). First, 
we assumed that the combination of ivermectin, 
diethylcarbamazine, and albendazole has the same 
macro ﬁ laricidal properties as albendazole and diethyl-
carba mazine (55%) and the remaining worms are 
sterilised permanently; this assumption was denoted 
IDA1. Second, we assumed that ivermectin, diethylcarba-
mazine, and albendazole has the same macroﬁ laricidal 
properties as albendazole and diethyl carbamazine (55%); 
this assumption was referred to as IDA2. These 
assumptions are compared with a counterfactual 
regimen of albendazole and diethylcarbamazine because 
we are only considering areas that are not co-endemic 
with onchocerciasis, which would prohibit use of 
diethylcarbamazine.
A pertinent question is, with a 100% eﬀ ective regimen, 
whether one round of treatment would be suﬃ  cient in 
driving the prevalence of microﬁ lariae below 1% 
(appendix p 1). To assess the eﬀ ect of one round of 
treatment, we used a simple model of infection in which 
every individual has either microﬁ laraemia or no 
infection (amicroﬁ laraemia), and the combined regimen 
of ivermectin, diethylcarbamazine, and albendazole is 
assumed to permanently clear microﬁ laraemia with 
100% eﬃ  cacy (IDA1). This estimate was compared 
with the counterfactual regimen (albendazole and 
diethylcarbamazine), assuming no transmission and 
23·1% clearance of microﬁ lariae.14
Research in context
Evidence before this study
We searched PubMed on Sept 20, 2016, with the terms 
“ivermectin”, “DEC”, “albendazole”, and “lymphatic ﬁ lariasis”. 
All studies that included ivermectin, diethylcarbamazine, and 
albendazole in a trial of individual clinical eﬀ ectiveness for 
lymphatic ﬁ lariasis infection were included. Findings showed 
that the triple-drug regimen resulted in a much stronger and 
more prolonged clearance of microﬁ laraemia. The aim of this 
study was to use simulation modelling to assess the potential 
eﬀ ect of a three-drug regimen of ivermectin, 
diethylcarbamazine, and albendazole for accelerating 
elimination of lymphatic ﬁ lariasis in diﬀ erent epidemiological 
settings.
Added value of this study
We used three transmission models to simulate the eﬀ ect of 
triple-drug mass drug administration in diﬀ erent scenarios and 
with diﬀ erent levels of coverage to estimate the added beneﬁ t of 
using ivermectin, diethylcarbamazine, and albendazole over 
standard two-drug regimens. Our analysis allowed us to 
extrapolate results from early clinical trial data to predict the likely 
outcome of subnational triple-drug mass drug administration 
programmes in diﬀ erent epidemiological settings.
Implications of all the available evidence
The triple-drug regimen has the potential to accelerate 
achievement of elimination goals for lymphatic ﬁ lariasis, 
particularly in areas with high baseline prevalence. However, 
a more eﬀ ective treatment will not overcome issues of poor 
population coverage or high systematic non-adherence in 
subsets of the population, because of the long lifespan of adult 
ﬁ larial worms. Therefore, a paradigm shift might be needed in 
how these programmes are rolled out to realise the potential of 
the triple-drug regimen and to relieve the burden of this 
debilitating disease. 
See Online for appendix
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Procedures
We compared three models of lymphatic ﬁ lariasis 
transmission to analyse the projected eﬃ  cacy of the 
triple-drug regimen of ivermectin, diethylcarbamazine, 
and albendazole: LYMFASIM, EPIFIL, and TRANSFIL 
(appendix pp 4–11).15–18 LYMFASIM and TRANSFIL 
are stochastic microsimulations including detailed 
descriptions of individuals’ burden as well as systematic 
non-adherence. EPIFIL is a deterministic, age-structured, 
population-based model of lymphatic ﬁ lariasis infection 
including a juvenile, adult worm, and microﬁ lariae stage 
as well as a larval stage in the mosquito population. 
All models have been ﬁ tted previously to various age-
structured microﬁ laraemia data (age-structured cross-
sectional data, trends in prevalence of microﬁ lariae 
during interventions, association between prevalence of 
microﬁ lariae and biting rate) and have been compared 
robustly with other data—eg, circulating ﬁ larial antigen 
prevalence.15,16,19–21 We assessed the models at their standard 
parameter settings so that every model’s most conﬁ dent 
predictions could be used, as they would have been if no 
direct comparison with other models were available. 
We then compared predictions for several standardised 
scenarios and elucidated the causes of diﬀ erences.
We presented the eﬀ ect of ivermectin, diethyl-
carbamazine, and albendazole in three typical scenarios, 
capturing a range of transmission settings (appendix p 3). 
First, we used an Asian setting with a 5% baseline 
prevalence of microﬁ lariae, where Culex species are 
dominant (eg, India, Sri Lanka, and Indonesia). Second, 
we used an African setting that is not co-endemic with 
onchocerciasis or loiasis, with 10% baseline prevalence of 
microﬁ lariae, where Anopheles species are dominant and 
bednet use is 0% or 50% (eg, Madagascar, Zambia, and 
Zimbabwe). Third, we used a setting of Papua New Guinea, 
with 40% prevalence of microﬁ lariae, where Anopheles 
species are dominant and bednet use is 0% or 50%.
To ascertain the eﬀ ect of population coverage 
and systematic non-adherence on the increased 
eﬀ ectiveness of ivermectin, diethylcarbamazine, and 
albendazole, we did a sensitivity analysis of these 
two factors in the TRANSFIL model. We chose 
population coverage levels of 55%, 65%, and 75%. 
We also considered high and low systematic non-
adherence, in which a randomly chosen individual’s 
decision on adhering to mass drug administration was 
the same as their decision in the previous round 25% of 
the time (low systematic non-adherence) or 75% of the 
time (high systematic non-adherence).
In areas where elimination campaigns are currently 
failing, several reasons could account for this occurrence, 
but it is diﬃ  cult to measure the main drivers of this 
behaviour. We used TRANSFIL to investigate the 
additional eﬀ ect of ivermectin, diethylcarbamazine, and 
albendazole under the three main hypotheses for why 
a campaign might be failing to achieve its goals after 
several rounds of mass drug administration (appendix p 3). 
The ﬁ rst hypothesis is that the burden of disease in the 
population is highly aggregated, meaning that some 
individuals are disproportionately more exposed than 
others. The second hypothesis is that strong systematic 
non-adherence occurs when a group of individuals 
consistently do not receive treatment. The third 
hypothesis is that poor population coverage might be 
present for individuals who are more highly exposed. For 
each possible hypothesis, we undertook ﬁ ve rounds of 
mass drug administration with the standard regimen, 
after which either the standard regimen was continued or 
the elimination campaign switched to the triple-drug 
regimen of ivermectin, diethyl carbamazine, and 
albendazole.
Statistical analysis
The primary outcome measure was the number of 
rounds of mass drug administration needed to reduce 
the prevalence of microﬁ lariae to below 1%, as recorded 
1 year after implementation (transmission assessment 
survey). Because two models assessed in the analysis of 
scenarios are stochastic in nature (LYMFASIM and 
TRANSFIL), and two models account for parameter 
uncertainty (EPIFIL and TRANSFIL), there will be 
uncertainty between runs. Therefore, we ran every 
scenario and eﬃ  cacy assumption for ivermectin, 
diethylcarbamazine, and albendazole 200 times.
We aggregated the probability of reducing the 
prevalence of microﬁ lariae to below 1% over all 
three models, using an equal weighting for all models. 
We also recorded the probabilities for the individual 
models.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
Figure 1: Eﬀ ect of one round of triple-drug mass drug administration
Plot shows the probability of achieving target prevalence (<1%) when baseline microﬁ lariae prevalence is 5% (blue 
line), 10% (green line), and 15% (red line). (Inset) Illustration of setting with 5% prevalence (red spots), 95% not 
infected (amicroﬁ laraemia; blue spots), and 65% population coverage (black circles).
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The corresponding author had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication.
Results
Figure 1 shows the eﬀ ect of one round of ivermectin, 
diethylcarbamazine, and albendazole. Even in settings 
with a low baseline prevalence of microﬁ lariae, the 
existing target of 65% population coverage is unlikely to 
reduce the prevalence to below 1% with one round of 
ivermectin, diethylcarbamazine, and albendazole. At a 
microﬁ lariae prevalence of 5%, a slight overlap can be 
seen between individuals who are infected and those who 
are treated at a coverage of 65% (ﬁ gure 1, inset), resulting 
in too small a reduction in prevalence. As population 
coverage increases, the probability of reducing micro-
ﬁ lariae to less than 1% rises markedly; however, the 
probability is only more than 80% when population 
coverage exceeds 80%. By comparison, the counterfactual 
regimen of albendazole and diethylcarbamazine had 
negligible probability (<0·1%) of reducing prevalence of 
microﬁ lariae to target levels for any level of population 
coverage (data not shown).
In the Asian scenario, with a low (5%) baseline 
prevalence of microﬁ lariae, the probability of achieving 
the target of less than 1% prevalence of microﬁ lariae was 
moderately high with both the triple-drug and two-drug 
regimens (ﬁ gure 2A). After three rounds of mass drug 
administration, averaged across models, the probability 
of achieving the target prevalence with the existing two-
drug regimen was 48%, compared with a 95% probability 
with the triple-drug regimen. However, after ﬁ ve rounds 
(the current standard protocol), the diﬀ erence between 
the regimens was smaller (95% with the two-drug 
regimen vs 100% with the triple-drug regimen). Larger 
gains were observed for the African scenario, with a 
moderate (10%) baseline prevalence of microﬁ lariae 
(ﬁ gure 2B). Here, the probability of achieving the less 
than 1% target prevalence after ﬁ ve rounds of mass drug 
administration was 55% for the two-drug regimen 
compared with 98% for the most optimistic, three-drug, 
100% worm sterilisation assumption (IDA1). In the Papua 
New Guinea scenario, with the highest (40%) baseline 
prevalence of microﬁ lariae, the probability of achieving 
Figure 2: Eﬀ ect of triple-drug regimen in areas with no previous mass drug 
administration
Plots show the probability of achieving target prevalence (<1%) with two-drug 
(blue line) and triple-drug (green and red lines) regimens. Solid lines indicate a 
model-averaged estimate and dashed lines are estimates from the individual 
models. (A) Low prevalence setting (Asia, Culex spp, 5% baseline prevalence of 
microﬁ lariae, no long-lasting insecticide-treated nets). (B) Moderate prevalence 
setting (Africa, not co-endemic with onchocerciasis, Anopheles spp, 10% baseline 
prevalence of microﬁ lariae, no long-lasting insecticide-treated nets). (C) High 
prevalence setting (Papua New Guinea, Anopheles spp, 40% baseline prevalence 
of microﬁ lariae, no long-lasting insecticide-treated nets). IDA1=ivermectin, 
diethylcarbamazine, and albendazole as eﬃ  cacious as two-drug regimen and 
100% worm sterilisation. IDA2=ivermectin, diethylcarbamazine, and 
albendazole as eﬃ  cacious as two-drug regimen.
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the target prevalence of less than 1% was greater with 
ﬁ ve rounds of the triple-drug regimen than with the 
standard two-drug regimen (6% with the two-drug 
regimen vs 50% with the triple-drug regimen; ﬁ gure 2C). 
When the number of rounds of mass drug administration 
rose to six, the triple-drug regimen increased the 
chances of reaching the target prevalence by a factor of 
ﬁ ve (16% vs 80%). Varying the proportion of worm 
sterilisation (90–100%) did not greatly aﬀ ect the 
probability of reaching the threshold target (appendix p 15).
Compared with the standard two-drug regimen, the 
number of rounds of mass drug administration needed 
to achieve the less than 1% target prevalence, and the 
probability of a large number of rounds being needed by 
chance for a particular parameter set (fewer outliers in 
the box plots; appendix pp 12, 13), was much lower with 
the triple-drug regimen. The amount of variation is 
diﬀ erent for every model, but the results are qualitatively 
consistent. The reduction in the range of rounds between 
the standard two-drug regimen and the triple-drug 
regimen was between four and ﬁ ve rounds for low, 
moderate, and high prevalence settings. This ﬁ nding can 
also be seen as reducing the likelihood of needing more 
than ﬁ ve rounds of mass drug administration.
Changing population coverage has a strong eﬀ ect on 
reducing the number of rounds needed to achieve less 
than 1% prevalence of microﬁ lariae, for both the triple-drug 
regimen of ivermectin, diethylcarbamazine, and alben-
dazole and the two-drug regimen of albendazole and 
diethylcarbamazine (ﬁ gure 3). Increasing coverage from 
65% to 75% reduces the number of rounds needed to have 
a 95% probability of reaching the target prevalence, from 
seven to three rounds for the two-drug regimen and from 
three to two rounds for the triple-drug regimen. High 
systematic non-adherence has a striking eﬀ ect on the 
outcome of mass drug administration with poor levels of 
coverage (55%) increasing the number of rounds needed 
to achieve 95% probability from seven to ten rounds for 
the two-drug regimen and four to eight rounds for the 
triple-drug regimen (appendix p 14). However, at higher 
levels of coverage (75%), the eﬀ ect is less severe, with the 
number of rounds needed for 95% probability increasing 
by one for both the two-drug and three-drug regimens.
The additive eﬀ ect of using long-lasting insecticide-
treated nets with mass drug administration was 
investigated for the scenarios from Africa and Papua 
New Guinea, where Anopheles spp is the dominant vector 
(ﬁ gure 4). Use of bednets had only a marginal eﬀ ect on 
the number of rounds of mass drug administration 
needed to reach the 1% microﬁ lariae prevalence 
0
20
40
60
80
100
Pr
ob
ab
ili
ty
 o
f a
ch
ie
vi
ng
 <
1%
 ta
rg
et
 (%
)
0
20
40
60
80
100
Pr
ob
ab
ili
ty
 o
f a
ch
ie
vi
ng
 <
1%
 ta
rg
et
 (%
)
0
20
40
60
80
100
Pr
ob
ab
ili
ty
 o
f a
ch
ie
vi
ng
 <
1%
 ta
rg
et
 (%
)
2 4 6 8 10
Rounds of mass drug administration (n)
A
C
B
Albendazole + diethylcarbamazine
IDA1
High non-adherence
Low non-adherence
Figure 3: Relative eﬀ ects of population coverage and systematic non-adherence
Plots show the probability of achieving target prevalence (<1%) with two-drug 
(blue line) and triple-drug (green line) regimens with high and low systematic 
non-adherence (dashed lines) when population coverage is (A) poor (55%), 
(B) standard (65%), and (C) high (75%). IDA1=ivermectin, diethylcarbamazine, 
and albendazole as eﬃ  cacious as two-drug regimen and 100% worm 
sterilisation. 
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threshold in both the moderate and high prevalence 
settings.
The table shows the number of rounds of mass drug 
administration needed to achieve a prevalence of 
microﬁ lariae less than 1% after the initial ﬁ ve rounds of 
mass drug administration, for every scenario related to 
stagnation of the elimination campaign. The triple-drug 
regimen was predicted to save one round of mass drug 
administration versus the two-drug regimen of albendazole 
and diethylcarbamazine, with a greater eﬀ ect when 
campaign stagnation was attributable to poor population 
coverage of heavily infected individuals in a setting of 
moderate prevalence, reducing the medium number of 
rounds from ten to six.
Discussion
The triple-drug regimen of ivermectin, diethyl-
carbamazine, and albendazole represents an exciting 
new development for GPELF and could potentially 
reduce signiﬁ cantly the number of doses of anthelmintic 
drugs needed by this WHO campaign. Several questions 
remain open surrounding the eﬃ  cacy of this triple-drug 
regimen at the population level and with respect to its 
ability to reinvigorate campaigns that have stagnated, 
as well as overcome issues such as poor population 
coverage or adherence. Here, we have shown a ﬁ rst step 
towards understanding these issues by comparing 
several diﬀ erent generic scenarios between the current 
regimen of albendazole and diethyl carba mazine and the 
new regimen of ivermectin, diethyl carbamazine, and 
albendazole, using three current models of lymphatic 
ﬁ lariasis infection.
Existing mass drug administration programmes are 
designed around what was perceived to be achievable 
eﬀ ective population coverage (65%) and duration to match 
the life expectancy of the adult worm (5 years). However, the 
level of coverage might not be enough to achieve elimination 
targets in all settings.15,22,23 Because ivermectin, diethyl-
carbamazine, and albendazole could lead to permanent 
sterilisation or killing of adult worms, shorter timeframes 
for campaigns can be considered, particularly if population 
coverage is higher. A shorter timeframe has the potential to 
reduce issues such as programme fatigue and poor coverage 
by allowing a more focused intervention and extra eﬀ ort to 
optimise coverage.
Although at least 65% population coverage is recom-
mended, many intervention units report higher levels.23 
Notwithstanding issues related to true coverage, both 
systematic non-adherence and the drug regimen have less 
of an eﬀ ect with high levels of coverage with respect to the 
probability of success for a campaign given a speciﬁ ed 
number of rounds (ﬁ gure 3). This ﬁ nding highlights that, 
with good population coverage, a campaign is able to 
overcome some of the possible stagnation issues.
In addressing the 2020 goals for elimination of 
lymphatic ﬁ lariasis, our results indicate that a campaign 
will have a greater probability of success if switching 
to ivermectin, diethylcarbamazine, and albendazole 
provides the same level of coverage as would be expected 
under the existing two-drug regimen. In a setting with 
moderate baseline prevalence of microﬁ lariae, the 
Figure 4: Eﬀ ect of bednets on eﬃ  cacy of triple-drug regimen
Boxplots show data for settings where Anopheles spp are the dominant vector. 
Red boxes denote scenarios without bednets and blue boxes denote scenarios 
with bednets. Solid black line represents the median round; coloured box 
represents the IQR; whiskers represent the 5th and 95th percentiles. 
(A) Moderate prevalence setting (Africa, Anopheles spp, 10% prevalence of 
microﬁ lariae, no previous mass drug administration). (B) High prevalence 
setting (Papua New Guinea, Anopheles spp, 40% prevalence of microﬁ lariae, 
no previous mass drug administration). 
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Albendazole and diethylcarbamazine 1 (1–2) 2 (1–3) 4 (1–13)
Ivermectin, diethylcarbamazine, 
and albendazole
1 (1–2) 1 (1–3) 4 (1–8)
Moderate prevalence setting
Albendazole and diethylcarbamazine 2 (1–8) 3 (1–9) 10 (1–14)
Ivermectin, diethylcarbamazine, 
and albendazole
1 (1–3) 2 (1–6) 6 (1–14)
Data are median number of rounds (95% CI). Based on simulations with TRANSFIL in a low prevalence setting 
(Asia, Culex spp, 5% prevalence of microﬁ lariae, no previous mass drug administration, no long-lasting insecticide-treated 
nets) and a setting with moderate prevalence (Africa, not co-endemic with onchocerciasis, Anopheles spp, 10% prevalence 
of microﬁ lariae, no previous mass drug administration, no long-lasting insecticide-treated nets).
Table: Analysis of hypotheses for failing elimination campaigns 
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probability of a campaign’s success increases by 70%; 
however, in a low prevalence setting, the gains are 
modest, only increasing the chances of success by 
about 20%. In high prevalence settings, the chances of 
success in achieving 2020 targets are only 35%.
At all levels of population coverage, systematic non-
adherence restricts the potential eﬀ ect of ivermectin, 
diethylcarbamazine, and albendazole. This ﬁ nding 
suggests that although more eﬀ ective, the triple-drug 
regimen is still susceptible to issues that limit the 
eﬀ ectiveness of current mass drug administration 
regimens.24 However, ivermectin, diethylcarbamazine, 
and albendazole consistently outperformed the current 
two-drug regimen in all simulation studies, including 
scenarios with high systematic non-adherence. This 
ﬁ nding shows that ivermectin, diethylcarbamazine, 
and albendazole can accelerate lymphatic ﬁ lariasis 
elimination programmes across various situations.
For the three models, there was variation in the 
number of rounds needed to push prevalence below 1% 
for each of the model runs. Stochastic variation and 
ﬂ uctuation in population parameters can lead to 
situations in which reduction in prevalence is more 
diﬃ  cult to achieve even when other variables—eg, the 
average infection rate—are constant. The extent of these 
more extreme cases was reduced when ivermectin, 
diethylcarbamazine, and albendazole was implemented, 
versus the current two-drug regimen of albendazole and 
diethylcarbamazine, particularly with high transmission. 
This ﬁ nding is especially encouraging for areas with 
high baseline prevalence of microﬁ lariae or for settings 
in which implementation of mass drug administration 
has so far been unable to reduce prevalence of lymphatic 
ﬁ lariasis to threshold targets.24
Our study has several limitations. First, because only 
a small study sample has been published up to now 
with respect to individual eﬃ  cacy of ivermectin, 
diethylcarbamazine, and albendazole, the eﬃ  cacy of 
the triple-drug regimen is still uncertain. Second, we 
did not aim to capture any speciﬁ c country scenario 
with our modelling analysis; rather, we used selected 
scenarios that were representative of conditions in 
endemic regions. Therefore, we aimed to investigate 
overall patterns. Finally, the outcome measure chosen 
in our study was the number of rounds of mass drug 
administration to achieve WHO pre-transmission 
assessment survey guidelines of less than 1% 
microﬁ laraemia to directly address policy-relevant 
questions about when speciﬁ c settings are able to move 
into the post-mass drug administration phase. However, 
a further question asks what the probability of 
elimination is once a region has entered the 
transmission assessment survey phase, which is not 
addressed here.
In conclusion, our modelling results suggest that the 
triple-drug regimen of ivermectin, diethylcarbamazine, 
and albendazole has great potential for accelerating 
elimination of lymphatic ﬁ lariasis in many settings, 
which is important in view of WHO’s ambitious target 
for global elimination by 2020. This study shows that 
although greater gains can be made with ivermectin, 
diethylcarbamazine, and albendazole, the regimen 
cannot fully overcome some challenges that mass drug 
administration campaigns face, such as systematic 
non-adherence and poor population coverage. However, 
if eﬀ ective coverage can be achieved, ivermectin, 
diethylcarbamazine, and albendazole should help 
countries achieve elimination of lymphatic ﬁ lariasis 
more quickly across a diverse number of settings.
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